It is also possible that such a mechanistic difference lies in SGLT2-Is potentially reducing stroke risk through cardiovascular and renal effects, whereas GLP1-RAs may impact stroke risk differently due to their predominantly cardiovascular actions and potential neuroprotective effects. This evidence concerns the gene SLC5A2 and stroke disorder.